Apolipoprotein CIII (apoCIII) plays an important role in plasma triglyceride and remnant lipoprotein metabolism. Because hypertriglyceridemia is an independent risk factor in coronary artery disease and the presence in plasma of triglyceride-rich remnant lipoproteins is correlated with atherosclerosis, considerable research efforts have been focused on the identification of factors regulating apoCIII gene expression to decrease its production. Here we report that the orphan nuclear hormone receptor Rev-erb␣ regulates the human apoCIII gene promoter. In apoCIII expressing human hepatic HepG2 cells, transfection of Rev-erb␣ specifically repressed apoCIII gene promoter activity. We determined by deletion and sitedirected mutagenesis experiments that Rev-erb␣ dependent repression is mainly due to an element present in the proximal promoter of the apoCIII gene. In contrast, we found no functional Rev-erb␣ response elements in the convergently transcribed human apoAI gene or the common regulatory enhancer. The identified Rev-erb␣ response element coincides with a ROR␣1 element, and in the present study we provide evidence that functional cross-talk between these orphan receptors modulates the apoCIII promoter. In vitro binding analysis showed that monomers of Rev-erb␣ bound this element but not another upstream ROR␣1 response element. In addition, we showed that the closely related nuclear orphan receptor RVR also specifically repressed the human apoCIII gene. These studies underscore a novel physiological role for members of the Rev-erb family of nuclear receptors in the regulation of genes involved in triglyceride metabolism and the pathogenesis of atherosclerosis.
Recent large scale clinical trials indicate that hypertriglyceridemia is an independent risk factor for coronary artery disease (1) (2) (3) (4) . In addition, triglyceride-rich remnant lipoproteins are positively correlated to the progression of atherosclerosis, which remains one of the leading causes of death in the Western world (5, 6) .
Apolipoprotein CIII (apoCIII) 1 is a key protein in plasma triglyceride metabolism. It is well established that the plasma concentration and synthesis rate of apoCIII are positively correlated with plasma triglycerides, both in normal and hypertriglyceridemic subjects (7) (8) (9) . In fact, apoCIII deficiency in humans results in increased catabolism of very low density lipoprotein particles (10) , whereas increased apoCIII synthesis is associated with hypertriglyceridemia (11) . Overexpression of human apoCIII in mice results in severe hypertriglyceridemia (12) , whereas disruption of the endogenous apoCIII gene protects the mice from postprandial hypertriglyceridemia (13) . apoCIII has been shown to delay the catabolism of triglyceriderich particles by several mechanisms (14 -17) , including inhibition of lipoprotein binding to the cell surface glycosaminoglycan matrix (17) and lipolysis by lipoprotein lipase (10, 18) . Moreover, studies with retinoids, fibrates, and other pharmacological agents show evidence that the modulation of apoCIII expression has an important role in hypertriglyceridemia (19 -23) . Therefore, the identification of factors capable of decreasing plasma apoCIII concentrations by down-regulation of its expression is of major importance for the treatment of dyslipidemia.
In humans, apoCIII is synthesized in the liver and, to a much lesser extent, in the intestine. The expression of apoCIII is strongly regulated at the transcriptional level, and the regulatory sequences responsible for the tissue-specific expression pattern of the apoCIII gene and for its modulation by signal transduction pathways have been extensively described (reviewed in Ref. 24) . The 5Ј-flanking region of the human apoCIII gene contains a proximal promoter and a distal regulatory enhancer (25) . The gene for apoCIII resides in an apolipoprotein gene cluster on chromosome 11q23 between the apoAI and apoAIV genes (26, 27) . The product of the convergently transcribed apoAI gene is the major protein component of high density lipoproteins. Plasma levels of apoAI and high density lipoprotein cholesterol correlate with each other, and both correlate inversely with the incidence of coronary heart disease (28, 29) . Importantly, the distal regulatory region of apoCIII acts as a common enhancer for the three genes of the cluster (24, 30 -32) .
The orphan nuclear receptor Rev-erb (NR1D) group contains two members in mammals: Rev-erb␣ (33) (34) (35) and RVR (also known as Rev-erb␤ and BD73) (36 -39) . Rev-erb receptors are widely expressed (33, 37) and have been described as negative transcriptional regulators of the Rev-erb␣ gene itself (40) as well as N-myc (41), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme (42) , ␣-fetoprotein (43) , and rat apoAI (44) genes. Rev-erb␣ mRNA is induced dramatically during adipogenesis (45) , and a role has also been proposed for both Rev-erb␣ and RVR in myogenesis (46) . However, the specific biological functions of these receptors in adipogenesis or in other physiological processes are still unknown.
Monomers of Rev-erb␣ and RVR bind to the six-nucleotide core motif PuGGTCA preceded by a 6-bp AT-rich region (36 -39, 47, 48) . In addition, homodimers of Rev-erb␣ and RVR bind to a direct repeat of the core sequence separated by two nucleotides with an AT-rich 5Ј extension (Rev-DR2) (40, 48) . Although the core binding site is recognized by the P-box/first helix of the DNA-binding domain, the precise recognition of the sequences 5Ј to the core binding site is determined by the C-terminal extension of the zinc finger domains (49) . Rev-erb␣ and RVR share a high degree of sequence similarity with the C-terminal extension/third helix of peroxisome proliferator-activated receptors (PPARs) (NR1C) and retinoic acid-related orphan receptors (RORs, also termed RZRs) (NR1F). As a consequence, Rev-erb␣ binds to the PPAR response elements of CYP4A6 and the hydratase/dehydrogenase bifunctional enzyme genes and interferes with the PPAR-dependent transactivation of the former gene (42, 49) . Conversely, the Rev-DR2 site described in the promoter of the human Rev-erb␣ gene is also a PPAR response element (50) . It should be noted that although the sequence determinants required for Rev-erb␣ and PPAR bindings are similar, they are not identical as evidenced by the incapacity of Rev-erb␣ to bind to the fatty acyl-CoA oxidase PPAR response element (42, 49) . The gene for N-myc, as well as the rat ␣-fetoprotein and apoAI genes, have been shown to contain elements that bind and are regulated by members of both Rev-erb and ROR␣ groups (41, 43, 44) . The sequence requirements for ROR␣, Rev-erb␣, and RVR are closely related (37) . Nevertheless, they are not identical (49) , so the putative cross-talk between those nuclear receptors should be analyzed in terms of case-by-case studies. We have learnt from Staels and co-workers (51) that ROR␣1 regulates apoCIII gene transcription through binding sites located in its proximal promoter. The importance of ROR␣ in apoCIII expression was underscored by studies with the staggerer mice, which carry a natural deletion in the ROR␣ gene (52) . These mice show decreased plasma triglyceride and apo-CIII levels compared with wild type mice (51) .
In this report, we demonstrate that Rev-erb␣ regulates the human apoCIII gene promoter. Rev-erb␣ represses transcription through one of the functional ROR␣1 response elements present in the apoCIII gene proximal promoter. Our results suggest a novel role for Rev-erb␣ in regulating triglyceride metabolism.
EXPERIMENTAL PROCEDURES
Plasmids-The 5Ј-flanking region of human apoCIII gene (nt Ϫ1408 to ϩ24, relative to the transcription start site) was obtained by PCR using human genomic DNA as a template (CLONTECH). Forward primer contained nt Ϫ1408 to Ϫ1383 and was tailed with a NheI restriction site. Reverse primer contained nt ϩ24 to ϩ2 and was tailed with a HindIII site. The PCR product was digested with NheI and HindIII and cloned into the corresponding sites of the promoter-less firefly (Photinus pyralis) luciferase reporter plasmid pGL3-basic (Promega), generating pϪ1408/ϩ24hC3LUC (also designated wild type). For the construction of pϪ108/ϩ24hC3LUC, a DNA fragment was generated by PCR using pϪ1408/ϩ24hC3LUC as a template and a NheI site tailed forward primer containing nt Ϫ108 to Ϫ86, with the reverse primer used for the former construction. The amplified promoter fragment was digested with NheI/HindIII enzymes and cloned into pGL3-basic vector. The 5Ј region of human apoAI gene (nt Ϫ1170 to ϩ235, relative to the transcription start site) was obtained by PCR using human genomic DNA as a template, a BglII site tailed forward primer containing nt Ϫ1170 to Ϫ1152 and a HindIII site tailed reverse primer containing nt ϩ235 to ϩ215. After digestion with BglII and HindIII, it was cloned into pGL3-basic vector to produce pϪ1170/ϩ235hAILUC. The 5Ј-flanking region of rat apoAI gene (nt Ϫ823 to ϩ31, relative to the transcription start site) was obtained by PCR using Sprague-Dawley rat genomic DNA as a template (CLONTECH), a NheI site tailed forward primer containing nt Ϫ823 to Ϫ804 and a HindIII site tailed reverse primer containing nt ϩ31 to ϩ10. The resulting fragment was cut with NheI and HindIII and then cloned in the corresponding sites of pGL3-basic vector to generate pϪ823/ϩ31rAILUC. Site-directed mutagenesis of the construct pϪ1408/ϩ24hC3LUC was accomplished using the QuikChange TM site-directed mutagenesis kit (Stratagene) according to the recommendations of the manufacturer and two pairs of 34-mer oligonucleotides containing mutations corresponding, respectively, to nt Ϫ21(G 3 A)/Ϫ22(G 3 C) and to nt Ϫ78(G 3 C)/Ϫ79(G 3 A) of human apoCIII promoter. The vector pGL3-TK contains a frag-FIG. 1. Rev-erb␣ represses the activity of the human apoCIII gene promoter. A, HepG2 cells were transiently transfected with a plasmid containing a luciferase reporter gene driven by the 5Ј-flanking region (Ϫ1408/ϩ24) of the human apoCIII gene or the empty pGL3-basic vector along with a plasmid expressing human Rev-erb␣ (200 ng) or the empty expression vector as control (pSG5). B, the reporter plasmid containing the Ϫ1408/ϩ24 region of human apoCIII cloned in front of the luciferase gene was cotransfected with increasing amounts of a Rev-erb␣ expression plasmid into HepG2 cells. Plasmid dosage was kept constant by the addition of empty expression vector. Luciferase activities were measured and expressed as described under "Experimental Procedures." The fold change relative to control level is shown for each construct. ment corresponding to nt Ϫ109 to ϩ20 of the TK gene promoter of herpes simplex virus (53) subcloned into the BglII/HindIII sites of pGL3-basic vector. The reporter plasmid pREVDR2-TKLUC was generated by insertion of a double-stranded oligonucleotide containing the Rev-DR2 response element of the human Rev-erb␣ gene promoter (5Ј-GATCCGGAAAAGTGTGTCACTGGGGCACA-3Ј) (40) into the BglII site of pGL3-TK. Similarly, three copies of a double-stranded oligonucleotide containing wild type (5Ј-GATCCGATATAAAACAGGTCAGAA-CCCTA-3Ј) or mutant (5Ј-GATCCGATATAAAACACATCAGAACCCT-A-3Ј) sequences spanning nt Ϫ33 to Ϫ11 and wild type (5Ј-GATCCTC-AGCAGGTGACCTTTGCCCAGCA-3Ј) or mutant (5Ј-GATCCTCAGCA-GGTGATGTTTGCCCAGCA-3Ј) sequences corresponding to nt Ϫ90 to Ϫ68 of human apoCIII gene promoter were inserted into the BglII site of pGL3-TK to generate, respectively, p(wtC3RE1) 3 -TKLUC, p(mutC3RE1) 3 -TKLUC, p(wtC3RE2) 3 -TKLUC, and p(mutC3RE2) 3 -TK-LUC. Plasmids expressing human cDNAs for Rev-erb␣, ROR␣1, and RVR were provided by J. A. Holt and J. T. Moore (GlaxoSmithKline, Research Triangle Park, NC). The backbone of those plasmids was the mammalian expression vector pSG5 with a modified polylinker. Plasmid DNA was prepared using the Qiagen endotoxin-free Maxipreparation method and quantitated spectrophotometrically. The integrities of all of the plasmids were verified by DNA sequencing.
Cell Transfection and Reporter Assays-Human hepatoblastoma HepG2 cells were cultured in basal Eagle medium supplemented with nonessential amino acids and 10% (v/v) fetal calf serum. On day 0, the cells were seeded on 24-well plates at a density of 3.5 ϫ 10 5 cells/well. On day 1, the cells were transfected with FuGENE 6 reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions. Typically, each well of a 24-well plate received 100 ng of firefly luciferase reporter plasmid and, when indicated, 0 -400 ng of plasmids expressing human Rev-erb␣, ROR␣1, or RVR. Effector plasmid dosage was kept constant by the addition of appropriate amounts of the empty expression vector pSG5. 10 ng/well of a sea pansy (Renilla reniformis) luciferase plasmid pRL-SV40 (Promega) was included in all transfections as an internal control for transfection efficiency. On day 3, the cell lysates were prepared by shaking the cells in 200 l of 1ϫ Promega lysis buffer for 10 min at room temperature. Firefly and Renilla luciferase activities were measured using a Dual-Luciferase ® Reporter Assay System (Promega) and a Lumistar luminometer (BMG Lab Technologies). Firefly luciferase activity values were divided by Renilla lucifer-
FIG. 2. Rev-erb␣ antagonizes ROR-
␣1-induced activation of the human apoCIII gene promoter. HepG2 cells were transfected with a plasmid containing a luciferase reporter gene driven by the 5Ј-flanking region (Ϫ1408/ϩ24) of the human apoCIII gene together with the empty expression vector pSG5 or a constant amount of the expression plasmid encoding human ROR␣1 (100 ng) and increasing amounts (0, 25, 50, and 100 ng) of the Rev-erb␣ expression plasmid. Plasmid dosage was kept constant by the addition of empty expression vector. The luciferase activities were measured and expressed as described under "Experimental Procedures."
FIG. 3.
Rev-erb␣ selectively represses the human apoCIII proximal promoter but not the human apoAI promoter. HepG2 cells were transfected with reporter plasmids containing the firefly luciferase gene driven by nt Ϫ1408/ϩ24 or Ϫ108/ϩ24 of the 5Ј-flanking region of the human apoCIII gene, the human apoAI (Ϫ1170/ϩ235), or rat apoAI (Ϫ823/ϩ31) genes or with the empty pGL3-basic vector as a negative control, along with expression plasmids encoding human ROR␣1 or human Rev-erb␣ (200 ng) or the empty pSG5 expression vector as control. The luciferase activities were measured and expressed as described under "Experimental Procedures." The fold change by Rev-erb␣ relative to control level is shown for each construct. Enhancer, distal regulatory enhancer; LUC, luciferase.
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ase activity values to obtain normalized luciferase activities. To facilitate comparisons within a given experiment, the activity data were presented as relative luciferase activities. All of the transfection experiments were performed at least three times, with each experimental point done in triplicate. The data are expressed as the means Ϯ S.D.
In Vitro Transcription/Translation and Electrophoretic Mobility Shift Analysis-Human Rev-erb␣ and human ROR␣1 proteins were synthesized in vitro from the corresponding expression plasmids in rabbit reticulocyte lysate by using TNT ® Quick Coupled transcription/ translation system (Promega) according to the instructions of the manufacturer. To obtain an unprogrammed lysate as a negative control for electrophoretic mobility shift analysis, a reaction was performed with the empty vector pSG5. Protein-DNA binding assays were performed as described (54) . Double-stranded oligonucleotides corresponding to the Rev-DR2 response element of human Rev-erb␣ gene promoter (RevDR2), wild type nt Ϫ33 to Ϫ11 (wtC3RE1), wild type nt Ϫ90 to Ϫ68 (wtC3RE2) of human apoCIII gene promoter (described under "Plasmids"), and a consensus sequence for the binding of monomers of Rev-erb␣ (47, 48) (consensus sequence) were radiolabeled by fill in with the Klenow fragment of DNA polymerase I. For the competition experiments, 10-, 50-, or 100-fold molar excess of unlabeled probes were included during a 10-min preincubation on ice. mtC3RE1 is a doublestranded oligonucleotide corresponding to a mutant sequence spanning nt Ϫ33 to Ϫ11 of human apoCIII promoter (described under "Plasmids"). The samples were electrophoresed at 4°C on a 4.5% polyacrylamide gel in 0.5ϫ TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8.0). The gels were dried and analyzed using a Molecular Dynamics PhosphorImager STORM 860 and ImageQuant software (Amersham Biosciences).
RESULTS
The Orphan Nuclear Receptor Rev-erb␣ Represses the Activity of the Human apoCIII Gene Promoter-To find factors capable of down-regulating the expression of the human apoCIII gene without affecting apoAI or other human lipid-related genes, we cloned their promoters in front of the firefly luciferase reporter gene and performed cotransfection experiments in the human hepatoblastoma cell line HepG2, which synthesizes apoCIII. Cotransfection of the human orphan nuclear receptor Rev-erb␣ expression plasmid resulted in a reduction of firefly luciferase activity driven by the 5Ј-flanking sequence of the human apoCIII gene (nt Ϫ1408 to ϩ24) (Fig. 1A) . The repression by Rev-erb␣ was promoter-dependent because it was not observed with the promoter-less pGL3-basic vector (Fig. 1A) or with constructs containing the promoter of human apoAI (see below) or other lipid-related genes (not shown). Furthermore, increasing amounts of the expression plasmid for Rev-erb␣ resulted in a dose-dependent inhibition of firefly luciferase activity (Fig. 1B) . As shown in Fig. 1B , the repression by Rev-erb␣ was already appreciable at low doses.
Rev-erb␣ Antagonizes Transactivation by ROR␣1 from Human apoCIII Gene Promoter-Transcription of human apo-CIII gene is regulated by the orphan nuclear receptor ROR␣1 (51) . Cross-talk between Rev-erb␣ and ROR␣1 has been re- apoCIII Regulation by Rev-erb␣ported in the rat ␣-fetoprotein far upstream enhancer (43) and the rat apoAI promoter (44) . Both receptors are expressed in HepG2 cells (37, 43, 50) . To investigate whether Rev-erb␣ could repress ROR␣1-induced transcriptional activity on human apo-CIII, we carried out transfection assays using the luciferase reporter plasmid containing the Ϫ1408/ϩ24 region of apoCIII along with expression plasmids for human Rev-erb␣ and ROR␣1 in HepG2. Cotransfection of human ROR␣1 led to a 2.5-fold induction over basal levels (Fig. 2) . We found that increasing amounts of Rev-erb␣ expression plasmid with constant levels of ROR␣1 efficiently decreased transactivation by ROR␣1 (Fig. 2) . These results suggest that the net transcriptional response from apoCIII promoter is influenced by the relative levels of Rev-erb␣ and ROR␣1 in the cells.
The Elements Required for Rev-erb␣-mediated Repression Are Located in the Proximal Promoter of apoCIII Gene-The 5Ј-flanking region of human apoCIII gene contains two ROR␣1 response elements (ROREs), both located in the proximal promoter (51) . As expected, the 5Ј deletion of 1.3 kilobase pairs led to a notable reduction in basal activity because of the lack of the strong distal regulatory enhancer (Fig. 3) . However, the fragment containing the first 108 bp of the apoCIII promoter, which harbors the functional ROREs, is still repressed by Reverb␣ (Fig. 3) .
The sequences immediately 5Ј to the start of transcription of both apoCIII and apoAI genes are significantly similar (55) , and the distal regulatory region of human apoCIII acts as an enhancer for the hepatic and intestinal expression of human apoAI gene expression (30 -32) . So we investigated whether Rev-erb␣ could somehow repress human apoAI gene. First, Vu-Dac and colleagues (44) have shown that Rev-erb␣ is able to repress the rat apoAI promoter but not the first 256 bp of the human apoAI promoter. We confirmed those results by using a reporter construct that contains a longer sequence of the human apoAI gene 5Ј-flanking region (Fig. 3) . We observed that, in contrast to rat apoAI or human apoCIII, neither Rev-erb␣ nor ROR␣1 have significant influence on the Ϫ1170/ϩ235 human apoAI promoter activity (Fig. 3) . Second, we next examined whether, in addition to the proximal promoter, any other Rev-erb␣ response element could be present in the distal regulatory enhancer of human apoCIII gene. For this purpose, we mutated by site-directed mutagenesis the two 6-bp core motifs AGGTCA present in the proximal promoter, which coincide with the half-sites of ROREs, in the context of the Ϫ1408/ϩ24 region of apoCIII gene (Fig. 4A) . We found that upon mutation of both half-sites (nt Ϫ21(G 3 A)/Ϫ22(G 3 C) and nt Ϫ78(G 3 C)/Ϫ79(G 3 A)), repression by Rev-erb␣ was lost (compare the 0.3-fold variation of the wild type construct with the 1.2-fold variation of the double mutant in Fig. 4B ). These results demonstrate that there is no other Rev-erb␣ response element in the distal enhancer. Fig. 4B indicate that each RORE present in apoCIII promoter contributes differently to the Rev-erb␣-mediated repression. When the Ϫ1408/ϩ24 region of apoCIII gene was mutated at the half-site of the RORE located at position Ϫ82/Ϫ71 (RORE2), therefore leaving an intact RORE site at Ϫ29/Ϫ18 (RORE1), the repression by Rev-erb␣ was still clearly observed. In contrast, mutation of only the half-site present in RORE1 almost completely abrogated Rev-erb␣ responsiveness, even with an intact RORE2 site (Fig. 4B) . These results indicate that the response to Rev-erb␣ is mainly mediated by the RORE site at Ϫ29/Ϫ18 (hereafter designated C3RE1) and that the contribution of the RORE site at Ϫ82/Ϫ71 (hereafter designated C3RE2), if any, is minimal.
Evaluation of the Contribution of Each RORE Present in apoCIII Promoter to Repression by Rev-erb␣-The data shown in
Specificity of Rev-erb␣ Binding-Electrophoretic mobility shift analyses were performed to determine whether Rev-erb␣ FIG. 5. Rev-erb␣ can specifically bind to the C3RE1 site of the human apoCIII promoter. Electrophoretic mobility shift analyses were performed using in vitro transcribed/translated human Rev-erb␣ (10 l), human ROR␣1 (5 l) or unprogrammed reticulocyte lysate (Ϫ), when indicated, and labeled double-stranded oligonucleotides corresponding to nt Ϫ90/Ϫ68 (C3RE2) (A) and nt Ϫ33/Ϫ11 (C3RE1) (B) of the human apoCIII gene promoter as described under "Experimental Procedures." The lysate volumes were kept constant by the addition of unprogrammed lysate. The competition experiments for binding of human Rev-erb␣ were performed by adding 10-, 50-, and 100-fold molar excess of the indicated unlabeled double-stranded oligonucleotides, whose identities are described under "Experimental Procedures." mtC3RE1 is identical to wtC3RE1 but with point mutations in the half-site (Ϫ21 (G 3 A) , Ϫ22(G 3 C)). CONS, consensus sequence for the binding of Rev-erb␣; wt, wild type.
apoCIII Regulation by Rev-erb␣could directly interact to the C3RE1 and C3RE2 sites. Incubation of a labeled double-stranded oligonucleotide containing the Ϫ29/Ϫ18 site (C3RE1) with in vitro translated human Reverb␣ resulted in a retarded complex (Fig. 5B, lane 2) . The binding was specifically competed by the addition of either the cold C3RE1 probe (Fig. 5B, lanes 3-5) or a cold probe representing a consensus sequence for the binding of Rev-erb␣ (Fig.  5B, lanes 9 -11) . In contrast, a cold double-stranded oligonucleotide (mtC3RE1) that is equivalent to C3RE1 but harbors point mutations in the half-site (nt Ϫ21(G 3 A)/Ϫ22(G 3 C) in Fig. 4A ) could not compete (Fig. 5B, lanes 6 -8) . Interestingly, this binding was not displaced by a cold probe containing the wild type site Ϫ82/Ϫ71 (C3RE2) (Fig. 5A, lanes 12-14) . The apparent incapacity of C3RE2 to bind Rev-erb␣ was further assessed by gel mobility shift assays using labeled C3RE2 probe. As shown on Fig. 5A , incubation of the C3R2 probe with ROR␣1 resulted in the formation of a visible retarded complex of C3R2 probe and ROR␣1 (Fig. 5B, lane 2) . In contrast, no retarded complexes were clearly detected from the incubation with Rev-erb␣ (Fig. 5B, lane 3) .
Rev-erb␣ Binds to apoCIII C3RE1 as a Monomer-Rev-erb␣ is capable of binding DNA as a monomer (47) or as a homodimer (40, 48) . To elucidate the binding mode of Rev-erb␣ to the human apoCIII gene promoter, we performed electrophoretic mobility shift analysis with: 1) labeled C3RE1 and C3RE2, 2) a labeled probe that binds in vitro to both monomers and dimers (RevDR2), and 3) a labeled probe that only binds monomers of Rev-erb␣ (consensus sequence). As shown in Fig.  6 , Rev-erb␣ binds as a monomer to C3RE1. Again, no retarded complexes between C3RE2 and Rev-erb␣ were clearly detected (Fig. 6, lane 7) . apoCIII C3RE1, but Not C3RE2, Confers Rev-erb␣ Responsiveness to Heterologous Promoters-To study whether either of these two sites could confer Rev-erb␣ responsiveness to an heterologous promoter, we linked three copies of the human apoCIII C3RE1 and C3RE2 sites upstream of the TK promoter and the luciferase gene. These reporter constructs along with human ROR␣1 and Rev-erb␣ expression vectors were then tested by cotransfection in HepG2 cells (Fig. 7) . A construct containing the Rev-DR2 element was used as a positive control. As expected, transfection of the ROR␣1 expression vector resulted in activation of both the wtC3RE1-and wtC3RE2-driven TK promoter constructs. However, reporter constructs with the TK promoter alone or driven by three copies of mutC3RE1 were not induced, which is in agreement with previous observations (51) . As demonstrated in Fig. 7 , wild type CR3RE1was able to confer Rev-erb␣-mediated repression to TK promoter, unlike the mutated CR3RE1 or wild type CR3R2. These data also show that the human apoCIII C3RE1 site was able to mediate functional cross-talk between ROR␣1 and Rev-erb␣ in HepG2 cells.
The Nuclear Orphan Receptor RVR Also Represses the Activity of Human apoCIII Gene Promoter-We were interested in determining whether RVR, a nuclear orphan receptor closely related to Rev-erb␣ that is also expressed in human liver and HepG2 cells (36) , could modulate the human apoCIII promoter activity. Cotransfection of a human RVR expression plasmid resulted in a significant reduction of firefly luciferase activity under the control of both the 5Ј-flanking sequence of human apoCIII gene (nt Ϫ1408 to ϩ24) and the apoCIII promoter site C3RE1-driven TK promoter (Fig. 8) , as well as the RevDR2-TK. The repression by RVR was specific because it was not observed on the promoter-less pGL3-basic vector or on the TK promoter alone. These results also show that the Rev-erb␣ response element of human apoCIII gene promoter confers RVR responsiveness to heterologous promoters (Fig. 8) .
DISCUSSION
It is well established that the expression of human apoCIII plays a key role in hypertriglyceridemia (10 -12, 19 -23) , whereas the concentration of the convergently transcribed apoAI, the major protein constituent of high density lipoproteins, contributes to the prevention of atherosclerosis (28, 56, 57) . Looking for factors capable of reducing the expression of apoCIII without having negative effects on human apoAI or other lipid-related genes, we found that human apoCIII is a selective target gene for orphan nuclear receptor Rev-erb␣. Here we show that this transcription factor specifically represses apoCIII through an element present in the promoter, which coincides with one of the two functional ROR␣1 response elements described previously (51) . Our results identify crosstalk between human Rev-erb␣ and ROR␣1 that is restricted to apoCIII proximal promoter and is not present in the distal common regulatory enhancer or in the promoter of human apoAI. Interestingly, this Rev-erb␣ response element (nt Ϫ29/ Ϫ18) overlaps the TATA box of apoCIII promoter (Fig. 4A) . It remains as an interesting question for future research to determine whether modulation of transcription by Rev-erb␣ could also involve cross-talk with the TATA-binding protein in this promoter. However, the contribution of this putative cross-talk to the net repression should not play an important part because we have demonstrated that this element can confer Rev-erb␣ responsiveness when cloned in front of the TK promoter. Strikingly, the Rev-erb␣ response element of the rat apoAI promoter FIG. 6 . Rev-erb␣ binds to the C3RE1 site of human apoCIII as a monomer. Electrophoretic mobility shift analyses were performed using in vitro transcribed/translated human Rev-erb␣ (10 l), human ROR␣1 (2.5 l), or unprogrammed reticulocyte lysate (Ϫ), when indicated, and labeled double stranded nucleotides containing the Rev-DR2 response element of the human Rev-erb␣ gene promoter (RevDR2), nt Ϫ33/Ϫ11 (C3RE1), and nt Ϫ90/Ϫ68 (C3RE2) of the human apoCIII gene promoter and a consensus sequence for the binding of monomers of Rev-erb␣ (CONS) as described under "Experimental Procedures." The lysate volumes were kept constant by the addition of unprogrammed lysate. Note that the shifted bands of probe C3RE2 (lanes 6 and 7) are unspecific. The mobilities of complexes containing dimers (D) and monomers (M) are indicated.
apoCIII Regulation by Rev-erb␣ (nt Ϫ32/Ϫ21) also overlaps the TATA box. This phenomenon gives further insight into the understanding of the process of the evolution of the apoAI and apoCIII genes from a common ancestor (58) .
Importantly, our findings are in accord with data showing an increase in the hepatic apoCIII mRNA levels in Rev-erb␣-deficient mice (59) . Based on the similarity between the sequence of the Rev-erb␣-responsive element of the mouse apo- FIG. 7 . The Rev-erb␣ response element present in the proximal promoter of the human apoCIII gene (C3RE1) confers Rev-erb␣ responsiveness to heterologous promoters. HepG2 cells were transiently transfected with plasmids expressing human ROR␣1 and/or human Rev-erb␣ or the empty pSG5 vector as control, together with reporter constructs containing three copies of the wild type (wtC3RE1) or mutant (mutC3RE1) sequence corresponding to nt Ϫ33/Ϫ11 or the wild type sequence of nt Ϫ90/Ϫ68 (wtC3RE2) of the human apoCIII gene promoter cloned in front of a heterologous TK promoter-driven luciferase. The Rev-DR2 response element of the human Rev-erb␣ gene promoter (RevDR2) in front of TK-luciferase was used as positive control. The empty pGL3-TK reporter vector was used as negative control. The plasmid dosage was kept constant by the addition of empty expression vector. The luciferase activities were measured and expressed as described under "Experimental Procedures. "   FIG. 8 . RVR also represses the activity of human apoCIII gene promoter. The Rev-erb␣ response element in the apoCIII promoter confers RVR responsiveness to heterologous promoters. HepG2 cells were transfected with expression plasmids encoding human Rev-erb␣ or human RVR (200 ng) or the empty pSG5 vector as control, along with a plasmid containing a luciferase reporter gene driven by the 5Ј-flanking region (Ϫ1408/ϩ24) of human apoCIII gene or the empty pGL3-basic (pGL3) vector as control. As well as a reporter construct containing three copies of the sequence corresponding to nt Ϫ33/Ϫ11 of human apoCIII gene promoter (C3RE1) cloned in front of a heterologous TK promoter-driven luciferase or the empty reporter vector pGL3-TK as a negative control. A reporter construct containing the Rev-DR2 response element of human Rev-erb␣ gene promoter (RevDR2) in front of TK-luciferase was used as positive control. The luciferase activities were measured and expressed as described under "Experimental Procedures."
apoCIII Regulation by Rev-erb␣CIII gene promoter and its human counterpart (55), these results in vivo can most likely be extended to the human apoCIII gene. On the other hand, although we have found that RVR also represses the apoCIII gene promoter, the Rev-erb␣ knockout mice data would indicate that RVR has no complete overlapping function compared with Rev-erb␣. Even so, it remains to be determined whether mice carrying at the same time disruptions of both Rev-erb␣ and RVR genes could have even higher levels of apoCIII expression.
Luciferase reporter assays made in the context of the natural promoter suggest that the other functional RORE, located in nt Ϫ82/Ϫ71, might have a slight contribution to Rev-erb␣-mediated repression of human apoCIII gene. However, in contrast to the site at Ϫ29/Ϫ18, it does not confer Rev-erb␣ responsiveness to a heterologous promoter. In addition, gel shift assays show that the binding of Rev-erb␣, if any, should be very weak. Conversely, we and others have shown that it confers a weak ROR␣1 responsiveness to the TK promoter and is capable of binding ROR␣1 in vitro (51) . This site discrimination underlines a somewhat different affinity of binding to DNA and suggests the hypothesis that functional ROREs in other promoters could be unresponsive to Rev-erb␣.
Our data and those reported previously demonstrate that the Rev-erb subfamily functions as dominant transcriptional repressors (40, 41, 44) . Some crystallography studies suggest that Rev-erb␣ is de facto an orphan receptor because of the small size or absence of a ligand pocket (60) . Furthermore, in contrast to most ligand-activated factors, ROR␣ receptors, which also still remain as orphan, and Rev-erb have arthropod homologues. Thus, it has been suggested that such orphans may represent ancestral receptors, before the evolution of ligands and/or ligand binding (61) . The lack of ligand have hampered further assessment on the biological role of both receptors. Nevertheless, the convergence of the opposite transcriptional effects played by Rev-erb and ROR␣ on a same gene suggests the existence of an orphan receptor-based signaling pathway. This mechanism should provide a fine tuning required for expression in response to a particular environmental or physiological cue. Because both subfamilies of receptors are expressed in human liver, the expression of apoCIII could be dictated, in part, by the ratio between the Rev-erb and ROR␣ hepatic expression levels. In addition, the regulation of those signals could presumably come from the cellular status of some coregulators that interplay with the orphans (62) .
Regulation of Rev-erb␣ expression has been achieved by treatment with fibrates (44, 50) and glucocorticoids (63) . Because fibrates increase the hepatic expression of Rev-erb␣ through a PPAR␣-mediated activation of the Rev-erb␣ gene promoter, it has been pointed out that Rev-erb␣ could play a functional role in the transcriptional repression of rat apoAI by fibrates (44) . As we have demonstrated, apoCIII promoter is repressed by Rev-erb␣. Therefore, it is tempting to speculate that Rev-erb␣ is involved in the previously reported repression of apoCIII gene by fibrates. Studies with PPAR␣ knockout mice have clearly demonstrated that PPAR␣ is required in the negative regulation of apoCIII gene expression by fibrates (64) . In (24) . Alternatively, in a multi-step process, PPAR-RXR could bind a Rev-DR2 element in Rev-erb␣ gene promoter (B), and increase its expression (50) . Then monomers of Rev-erb␣ antagonize activation by ROR␣1 and repress the activity of human apoCIII promoter (C). Moreover, upon activation of PPAR␣, the negative autoregulation of Rev-erb␣ (40) could be diminished because of a competition between PPAR-RXR and homodimers of Rev-erb␣ (50) .
apoCIII Regulation by Rev-erb␣contrast, the involvement of other factors in the transcriptional repression by these agents is still unclear. The hepatocyte nuclear factor-4 (HNF-4) (NR2A1) is a receptor required for the hepatic expression of apoCIII (24, 65) . This liver-enriched transcription factor strongly activates the human apoCIII promoter activity through its binding to the previously described proximal element CIIIB (nt Ϫ92/Ϫ67) and thereby mediates transactivation by the transforming growth factor-␤ signal transduction pathway (24, 25) . Hertz et al. (23) showed that the transcriptional suppression of apoCIII exerted by fibrates is due to direct and indirect complementary modes of actions: 1) displacement of HNF-4 from the element CIIIB in the apoCIII promoter mediated by nonproductive PPAR-RXR binding (Fig.  9) and 2) transcriptional suppression of HNF-4 levels. The former mechanism, however, needs further analysis because Vu-Dac et al. (44) could not confirm any significant regulation of HNF-4 gene expression in livers of animals treated with fibrates. Here we propose an alternative or an additional mechanism for PPAR␣-mediated negative regulation of apoCIII promoter by fibrates, namely, repression by an increase in PPAR␣-induced Rev-erb␣ levels (Fig. 9) . Despite exhaustive efforts we have not been able to demonstrate a direct implication of Reverb␣ in the repression by fibrates. Although studies in animals show a clear suppression of hepatic expression of apoCIII by treatment with fibrates, we, as well as others (66, 67) , could not observe these effects in cultured hepatocytes, most likely because the response to fibrates is dependent on the serum used in the culture medium (68) . This paradox suggests that other factors, in addition to PPAR␣ and Rev-erb␣, should be involved in the negative regulation by fibrates. On the other hand, treatment of rats with dexamethasone results in a decrease of hepatic Rev-erb␣ mRNA levels. Interestingly, consistent with this observation, dexamethasone increases hepatic apoCIII mRNA in mice (69) and elevates plasma triglycerides in humans (70) . It will be of interest to determine whether glucocorticoids also increase human apoCIII expression and to investigate a putative involvement of Rev-erb␣.
In conclusion, our results have shown that Rev-erb␣ specifically inhibits human apoCIII promoter gene activity. These data underscore a physiological role for Rev-erb␣ in the regulation of genes involved in triglyceride metabolism and, therefore, identify Rev-erb␣ as a potential pharmacological target for the treatment of hypertriglyceridemia.
